Reported 2 months ago
Novo Nordisk has cut its full-year profit outlook after reporting lower-than-expected sales of its weight-loss drug Wegovy in the second quarter. This disappointing performance has raised concerns among investors, especially with increasing competition from Eli Lilly. Following the news, Novo's shares experienced a significant decline, leading to questions about its dominance in the rapidly growing obesity drug market.
Source: YAHOO